endoluminal solutions, Inc. held its 2nd Annual General Meeting of Shareholders on October 13, 2026.
The meeting opened with remarks from Kiyokazu Nakajima, Founder and Director, CSO (Chief Scientific Officer), followed by Takuya Kanda, Representative Director and CEO, who chaired the meeting. Reports were presented on the financial results for the second fiscal year, the progress of product development, and the upcoming development schedule.
The meeting also covered the features and market positioning of our disposable endoscope for gastric cancer screening, as well as plans for entering the Chinese market and establishing a joint venture, future international expansion, fundraising strategies, and a potential initial public offering (IPO). These discussions provided an opportunity to share our strategic direction for future growth with our shareholders.
We will continue to strengthen our research and development capabilities and business foundation, accelerate the practical application and real-world implementation of innovative medical devices and systems, and contribute to addressing the challenges of gastric cancer screening.
